Novartis-Imatinib-India case


[Business Standard]

The Supreme Court will start final hearing next month on a plea by Swiss pharma firm Novartis AG challenging the order of an appellate board, which upheld the government’s denial of patent to its blood cancer drug Glivec.

A Bench, comprising Justices Dalveer Bhandari and Deepak Verma, directed today to list the matter for final hearing in March.

Listed for hearing on 09/08/2011 (update: Moneycontrol news)

Background: Novartis’ imatinib crystalline form application [1602/MAS/1998] rejected in pre grant opposition and also in appeal at IPAB . This case is precedential for the term “efficacy” of section 3(d) (efficacy=therapeutic efficacy). Now the appeal of IPAB order lies with supreme court.

Advertisements

About Guna

Interested to learn things around me
This entry was posted in Patent case and tagged , , , , . Bookmark the permalink.

One Response to Novartis-Imatinib-India case

  1. Pingback: World Spinner

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s